Edgewise Therapeutics (EWTX) Assets Average (2021 - 2026)

Edgewise Therapeutics (EWTX) has 6 years of Assets Average data on file, last reported at $535.6 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 13.8% year-over-year to $535.6 million; the trailing twelve-month figure through Mar 2026 stood at $535.6 million (up 13.8% YoY), and the FY2025 full-year result was $519.7 million, up 25.71% from the prior year.
• Assets Average slipped to $535.6 million in Q1 2026, from $568.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $598.4 million in Q3 2025 to a low of $265.1 million in Q2 2022.
• A 5-year average of $428.9 million and a median of $446.9 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average retreated 13.76% in 2022 and jumped 62.45% in 2024, its largest moves.
• Tracing EWTX's Assets Average over 5 years: stood at $372.1 million in 2022, then decreased by 12.48% to $325.7 million in 2023, then jumped by 53.22% to $499.0 million in 2024, then grew by 13.82% to $568.0 million in 2025, then declined by 5.72% to $535.6 million in 2026.
• Business Quant data shows EWTX's Assets Average at $535.6 million in Q1 2026, $568.0 million in Q4 2025, and $598.4 million in Q3 2025.